Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS

Bookmark and Share
Published: 14 Jun 2019
Views: 1207
Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France

Dr Pierre Fenaux presents results at the 2019 European Hematology Association (EHA) Annual Meeting from IMerge study.

Use of single-agent imetelstat yielded an 8-week transfusion independence rate of 45%, with a median duration of 8.5 months and all patients with IPSS-R intermediate and poor cytogenetic risk responded.